Clinical trial Recruiting at 1 site Phase1; Phase2 Interventional Ages 21 to 70

Atomoxetine and DAW2020 for treating obstructive sleep apnea

Official title: Effect of Atomoxetine and DAW2022 on OSA Severity

Run by Brigham and Women's Hospital · NCT05350215 · Data updated 2026-11-12

This study is testing if a combination of two medications can help people with obstructive sleep apnea breathe better while they sleep.

Quick facts

PhasePhase1; Phase2
Study typeInterventional
Ages21 Years to 70 Years
SexAll
Enrollment18 (estimated)
SponsorBrigham and Women's Hospital
Academic / other
Locations1 site (Boston, Massachusetts)
StatusRecruiting
StartedJune 1, 2022
Main results expectedDecember 1, 2026
Study endsDecember 1, 2026
Registry record updatedJuly 10, 2026
Trial IDNCT05350215 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals diagnosed with moderate-to-severe obstructive sleep apnea, characterized by an apnea-hypopnea index (AHI) of 15 events per hour or more.

Probably not a fit

Patients with other significant respiratory disorders, major organ system diseases, or those on medications that affect respiration may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of atomoxetine and DAW2020 on the severity of obstructive sleep apnea (OSA). Participants will undergo two overnight sleep studies, one with the drug combination and one with a placebo, to monitor sleep and respiratory variables. The study aims to assess the efficacy of these medications in reducing OSA severity while minimizing side effects associated with previous treatments. A thorough medical history and physical examination will be conducted prior to each study night.

Why it matters

Potential benefit: If successful, this study could provide a new treatment option for patients with moderate-to-severe obstructive sleep apnea.

How similar studies have gone: Previous studies have shown promising effects of atomoxetine and oxybutynin on OSA severity, but this specific combination with DAW2020 is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Moderate-to-severe OSA (AHI ≥ 15 events/hr)

Exclusion Criteria:

* All participants will be healthy and without major organ system disease that would preclude undergoing the physiological measurements.
* Use of medications expected to stimulate or depress respiration (including opioids, barbiturates, acetazolamide, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid).
* Use of SNRIs/SSRIs.
* Conditions likely to affect OSA physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition.
* Sleep disordered breathing or respiratory disorders other than obstructive sleep apnea:
* Other sleep disorders: periodic limb movements (periodic limb movement arousal index \> 10/hr), narcolepsy, or parasomnias.
* Hypersensitivity to the study drug (angioedema or urticaria)
* Contraindications to DAW2020
* Use of medications that lengthen QTc interval
* Hypokaliemia, hypomagnesemia, uncontrolled thyroid disease
* Severe claustrophobia.

Where it's running

  • Brigham and Women's Hospital
    Boston, Massachusetts, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.